trending Market Intelligence /marketintelligence/en/news-insights/trending/W5_asE6uOGTteEITZmvlUA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Botanix acne therapy fails to reduce inflammatory lesions in midstage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Botanix acne therapy fails to reduce inflammatory lesions in midstage study

Botanix Pharmaceuticals Ltd. will advance the acne therapy BTX 1503 into a phase 3 clinical trial despite its failure to beat placebo in a midstage study.

Trading was initially halted on the Australian Stock Exchange on the news, but upon market open on Oct. 23, the stock had fallen by half, dropping from 24 Australian cents down to 12 Australian cents.

The Australian biotech company, which focuses on the development of cannabis-based therapies, was evaluating three different doses of its acne therapy compared to once- or twice-daily doses of placebo in the phase 2 study. Patients received either 5% or 2.5% BTX 1503 daily, or a 5% dose of the drug twice daily.

After 12 weeks of treatment, all doses of BTX 1503 reduced inflammatory lesions in acne patients older than 12 years, Botanix noted in its Oct. 22 news release. The group getting a once-daily dose of 5% BTX 1503 saw the highest efficacy with an average reduction in lesions of 40.54%. But the drug did not beat placebo, which saw a 40.15% reduction in lesions.

The trial did, however, meet a secondary goal of reducing non-inflammatory lesions.

Botanix will have a phase 2 completion meeting with the U.S. Food and Drug Administration, and is planning to move the therapy on to a phase 3 clinical trial.